ADR120S

ADR120S EBITDA per Employee

The EBITDA per Employee of ADR120S (3750.T) as of Nov 4, 2026 is -14.16 M JPY. In the previous year, EBITDA per Employee was -11.83 M JPY — a change of 19.66% (lower).

EBITDA per Employee

-14.16 MJPY

YoY

19.66%

Last updated:

EBITDA per Employee of ADR120S is 2026 -14.16 M JPY. EBITDA per Employee of ADR120S was 2025 -11.83 M JPY. It decreases by 19.66% lower compared to the previous year.

The ADR120S EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2019
5.16 M JPY
Jan 1, 2020
7.64 M JPY
Jan 1, 2021
-7.93 M JPY
Jan 1, 2022
-3.53 M JPY
Jan 1, 2023
-8.03 M JPY
Jan 1, 2024
-8.82 M JPY
Jan 1, 2025
-11.83 M JPY
Jan 1, 2026
-14.16 M JPY
The ADR120S EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-14.16 MJPY+19.66%
-11.83 MJPY+34.19%
-8.82 MJPY+9.80%
-8.03 MJPY+127.61%
-3.53 MJPY-55.53%
-7.93 MJPY-203.83%
7.64 MJPY+48.11%
5.16 MJPY+138.79%
2.16 MJPY-134.71%
-6.23 MJPY+63.52%
-3.81 MJPY-159.57%
6.39 MJPY+27.92%
5.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ADR120S Stock analysis

What does ADR120S do? ADR120S Inc generates revenue through its Real Asset segment, which involves buying and selling real estate, developing and operating hotels, and investing in real estate projects. The Medical segment focuses on regenerative medicine, selling medical equipment like the Celusion centrifuge and Celusion cell therapy kit, and providing cell therapy services. The company serves clients in real estate development, hotel operations, and healthcare sectors, with products targeting medical facilities and clinics specializing in regenerative treatments. The Real Asset segment handles property transactions, hotel management, and real estate investments, while the Medical segment offers cell therapy solutions through its branded products. Both segments target businesses seeking to expand in real estate or adopt advanced medical technologies, with the Celusion products being key revenue drivers in the healthcare market. ADR120S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ADR120S stock

EBITDA per Employee of ADR120S is -14.16 M JPY in 2026.

EBITDA per Employee of ADR120S changed from -11.83 M JPY to -14.16 M JPY, representing a 19.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee ADR120S since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's ADR120S historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — ADR120S

All Key Metrics — ADR120S